The Scientific and Standardization Committee (SSC) is a permanent committee of the ISTH and the scientific working arm that handles the ongoing, scientific work of the Society. The SSC is comprised of 21 Subcommittees and one working group addressing a specific problem related to thrombosis, disorders of hemostasis and their underlying vascular biology.
Each Subcommittee is led by a Chair and up to 8 Co-Chairs who have significant expertise in the Subcommittee's area of interest. Two Co-Chair positions are reserved for an Early Career ISTH member and a Reach-the-World Member, to foster a diverse and inclusive community within the Subcommittees. The Chair and Co-Chairs are responsible for overseeing the Subcommittee's projects on standardization, nomenclature and guidance. In addition to these nine Subcommittee members, many other experts contribute to the projects and work of each Subcommittee.
Each year, following the annual ISTH Congress, some Co-Chairs rotate off each Subcommittee, giving new experts an opportunity to serve on a Subcommittee. Kindly complete the form below to express interest in participating on a Subcommittee.
Please note, there are a limited number of positions available and there is no guarantee of selection for a position.Please note: Co-Chairs must be active ISTH members and are appointed to a 2-year term with the option
to serve an additional 2 years, for a total of four years.
According to the SSC Rules and Guidelines, an ISTH member may only serve on one SSC Subcommittee at a time.Co-chair Openings by Subcommittee:
- Biorheology [newly renamed: Biorheology, Biomaterials, and Bioengineering (B3)]: 2 openings (1 RTW)
- Control of Anticoagulation [newly renamed: Thrombosis and Antithrombotic Therapies]: 2 openings
- Disseminated Intravascular Coagulation: 0 openings
- Factor VIII, IX and Rare Coagulation Disorders : 1 opening
- Factor XI and the Contact System: 1 opening
- Factor XIII & Fibrinogen: 2 openings
- Fibrinolysis: 0 openings
- Genomics in Thrombosis & Hemostasis [newly renamed: OMICS in Thrombosis and Hemostasis]: 0 openings
- Hemostasis & Malignancy [newly renamed: Cancer-Associated Thrombosis and Hemostasis]: 0 openings
- Hemostatic Management of Patients with Liver Disease [newly renamed: Hemostasis and Thrombosis in Liver Disease]: 1 opening (RTW)
- Lupus Anticoagulant/Antiphospholipid [newly renamed: Antiphosopholipid Syndrome]: 3 openings
- Models of Thrombosis & Hemostasis: 3 openings
- Pediatric/Neonatal Thrombosis & Hemostasis: 4 openings
- Perioperative & Critical Care Thrombosis & Hemostasis: 3 openings
- Physiological Anticoagulants and Thrombophilia: 1 opening (RTW)
- Platelet Immunology [newly renamed: Immune-Mediated Platelet Disorders]: 2 openings
- Platelet Physiology [newly renamed: Platelets in Health and Disease]: 1 opening
- Predictive/Diagnostic Variables [newly renamed: Diagnosis and Prediction in Thrombotic Disease]: 0 openings
- Vascular Biology [newly renamed: Vascular Biology and Immunothrombosis]: 3 openings (1 RTW)
- Von Willebrand Factor: 2 openings
- Women's Health Issues in Thrombosis & Hemostasis: 1 opening